NMO Spectrum Disorder Clinical Trial
Official title:
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders (BEAT NMO)
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Belimumab (Benlysta ®) is a human immunoglobulin G1λ monoclonal antibody that inhibits B-cell survival and differentiation by neutralizing soluble B lymphocyte stimulator. Belimumab may benefit some patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD. Clincial trials may be needed to observe its efficacy and safety.
The investigators primarily aim to observe the time to first relapse from initiation of belimumab treatment. The secondary outcomes are to determine: The safety profile of belimumab in participants with NMO and whether belimumab improves Expanded Disability Status Scale (EDSS), et al. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03829566 -
Autologous Transplant To End NMO Spectrum Disorder
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT05432713 -
A Study of LP-168 in Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT04822623 -
Imaging Evaluation of Central Nervous Autoimmune Diseases
|
||
| Completed |
NCT04227470 -
A Study of HBM9161 in NMOSD Patients
|
Phase 1 | |
| Not yet recruiting |
NCT06280755 -
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
|
||
| Recruiting |
NCT05414890 -
Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
|
||
| Recruiting |
NCT05840055 -
ACT With NMOSD Patients and Caregivers Pilot Study
|
N/A | |
| Recruiting |
NCT05004493 -
Biorepository and Registry for Plasma Exchange Patients
|
||
| Completed |
NCT05896605 -
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder
|
Phase 4 | |
| Recruiting |
NCT04106830 -
Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE)
|
||
| Completed |
NCT03766347 -
Pediatric NMOSD Observational Study
|
||
| Recruiting |
NCT05154370 -
China National Registry of Neuro-Inflammatory Diseases
|
||
| Recruiting |
NCT06443333 -
National, Multicentric Registry Study on Neuroimmunological Diseases in China
|
||
| Recruiting |
NCT05145361 -
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
|
Early Phase 1 | |
| Not yet recruiting |
NCT05974293 -
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
|
Phase 2 | |
| Completed |
NCT04355611 -
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
|
||
| Recruiting |
NCT05792462 -
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
|
Phase 1/Phase 2 |